Active substance
Results for the substance rozanolixizumab
1 result
About this active substance
Rozanolixizumab is a humanized monoclonal antibody used in the treatment of antibody-mediated autoimmune diseases, such as generalized myasthenia gravis. It works by binding to the neonatal Fc receptor (FcRn), reducing circulating immunoglobulin G (IgG) levels and, consequently, the activity of pathogenic autoantibodies.
Rozanolixizumab is administered as a subcutaneous infusion, typically as part of a personalized therapeutic regimen. It is often used in patients who do not respond adequately to conventional therapies or who experience significant side effects from other treatments.
Common side effects include injection site reactions, headache, fatigue, and nausea. In rare cases, severe infections or allergic reactions may occur. Careful monitoring is essential to ensure the safety and efficacy of the treatment.
Rozanolixizumab represents an innovation in the treatment of autoimmune diseases, offering a targeted therapeutic option for patients with antibody-mediated conditions.
Rozanolixizumab is administered as a subcutaneous infusion, typically as part of a personalized therapeutic regimen. It is often used in patients who do not respond adequately to conventional therapies or who experience significant side effects from other treatments.
Common side effects include injection site reactions, headache, fatigue, and nausea. In rare cases, severe infections or allergic reactions may occur. Careful monitoring is essential to ensure the safety and efficacy of the treatment.
Rozanolixizumab represents an innovation in the treatment of autoimmune diseases, offering a targeted therapeutic option for patients with antibody-mediated conditions.